Communicating with Payers: Practical Guidance for Sparsentan Access in FSGS

In "Communicating with Payers: Practical Guidance for Sparsentan Access in FSGS," the panel closes the series with practical guidance on aligning payer coverage with the evidence behind sparsentan.

Dr. Campbell asks how payer coverage criteria should be worded given the gap between DUPLEX's trial inclusion rules and the broader FDA label. Dr. Trachtman argues that if a patient has proteinuria above 1.5 grams and a physician prescribes sparsentan, coverage should follow, with clinical judgment guiding use rather than the trial's stricter enrollment criteria. He stresses that careful, timely follow-up should justify continued coverage rather than closing the door on the drug outright, placing the burden on practitioners to confirm effectiveness and safety over time. Asked for practical advice on communicating with payers, Dr. Trachtman points clinicians toward the DUPLEX summary data as the strongest available evidence, and urges providers to advocate directly for patients, since confirmed FSGS carries roughly a 40% to 50% chance of progressing to kidney failure within five to ten years and sparsentan remains the only approved therapy. He calls for collaboration with patient advocacy groups to help payers recognize that risk, alongside disciplined monitoring so resources aren't wasted on ineffective treatment.

Dr. Trachtman emphasizes that real-world, post-approval data on proteinuria reduction and kidney function preservation will be essential for updating both the FDA and payers as more evidence accumulates over time. Asked for final takeaways, Dr. Trachtman calls DUPLEX's completion, by the sponsor, investigators, and patients, a monumental accomplishment and the first step in an ongoing dialogue between patients, regulators, and payers, rather than a finished answer. He reminds payers that untreated, unresponsive FSGS carries real costs, in lost work and school time and progression to end-stage disease, that can outweigh a drug's sticker price. Dr. Campbell agrees, noting a promising therapeutic pipeline behind sparsentan and expressing hope that FSGS care is entering a precision-medicine era with multiple treatment options ahead for patients.

Thank you for watching this Managed Healthcare Executive Between The Lines series on focal segmental glomerulosclerosis. Please subscribe to our eNewsletter for information on upcoming video series.